Literature DB >> 8826854

Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.

S Dhar1, P Nygren, K Csoka, J Botling, K Nilsson, R Larsson.   

Abstract

Differential drug response in a human cell line panel representing defined types of cytotoxic drug resistance was measured using the non-clonogenic fluorometric microculture cytotoxicity assay (FMCA). In total 37 drugs were analysed; eight topoisomerase II inhibitors, eight anti-metabolites, eight alkylating agents, eight tubulin-active agents and five compounds with other or unknown mechanisms of action, including one topoisomerase I inhibitor. Correlation analysis of log IC50 values obtained from the panel showed a high degree of similarity among the drugs with a similar mechanism of action. The mean percentage of mechanistically similar drugs included among the ten highest correlations, when each drug was compared with the remaining data set, was 100%, 92%, 88% and 52% for the topoisomerase II inhibitors, alkylators, tubulinactive agents and anti-metabolites respectively. Classification of drugs into the four categories representing different mechanisms of action using a probabilistic neural network (PNN) analysis resulted in 29 (91%) correct predictions. The results indicate the feasibility of using a limited number of cell lines for prediction of mechanism of action of anti-cancer drugs. The present approach may be well suited for initial classification and evaluation of novel anti-cancer drugs and as a potential tool to guide lead compound optimisation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8826854      PMCID: PMC2074735          DOI: 10.1038/bjc.1996.453

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  47 in total

1.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

2.  Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26).

Authors:  M K Danks; J C Yalowich; W T Beck
Journal:  Cancer Res       Date:  1987-03-01       Impact factor: 12.701

3.  Role of the glutathione redox cycle in acquired and de novo multidrug resistance.

Authors:  R A Kramer; J Zakher; G Kim
Journal:  Science       Date:  1988-08-05       Impact factor: 47.728

Review 4.  The cell biology of multiple drug resistance.

Authors:  W T Beck
Journal:  Biochem Pharmacol       Date:  1987-09-15       Impact factor: 5.858

5.  Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation.

Authors:  W S Dalton; T M Grogan; J A Rybski; R J Scheper; L Richter; J Kailey; H J Broxterman; H M Pinedo; S E Salmon
Journal:  Blood       Date:  1989-02-15       Impact factor: 22.113

6.  Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

Authors:  W S Dalton; T M Grogan; P S Meltzer; R J Scheper; B G Durie; C W Taylor; T P Miller; S E Salmon
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

7.  Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.

Authors:  W T Beck; M C Cirtain; M K Danks; R L Felsted; A R Safa; J S Wolverton; D P Suttle; J M Trent
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

8.  Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein.

Authors:  W S Dalton; B G Durie; D S Alberts; J H Gerlach; A E Cress
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

9.  Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.

Authors:  S E Mirski; J H Gerlach; S P Cole
Journal:  Cancer Res       Date:  1987-05-15       Impact factor: 12.701

10.  Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.

Authors:  K Csoka; J Liliemark; R Larsson; P Nygren
Journal:  Semin Oncol       Date:  1995-08       Impact factor: 4.929

View more
  15 in total

1.  Ligatoxin B, a new cytotoxic protein with a novel helix-turn-helix DNA-binding domain from the mistletoe Phoradendron liga.

Authors:  Shi-Sheng Li; Joachim Gullbo; Petra Lindholm; Rolf Larsson; Eva Thunberg; Gunnar Samuelsson; Lars Bohlin; Per Claeson
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

2.  Characterization of the cytotoxic activity of the indoloquinoline alkaloid cryptolepine in human tumour cell lines and primary cultures of tumour cells from patients.

Authors:  Daniel Laryea; Anders Isaksson; Colin W Wright; Rolf Larsson; Peter Nygren
Journal:  Invest New Drugs       Date:  2008-10-14       Impact factor: 3.850

3.  Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug.

Authors:  Henrik Lövborg; Robert Burman; Joachim Gullbo
Journal:  BMC Res Notes       Date:  2009-06-29

Review 4.  Is resistance useless? Multidrug resistance and collateral sensitivity.

Authors:  Matthew D Hall; Misty D Handley; Michael M Gottesman
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

5.  Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro.

Authors:  C Etievant; J M Barret; A Kruczynski; D Perrin; B T Hill
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

6.  In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies.

Authors:  Kristina Wiberg; Kristina Carlson; Anna Aleskog; Rolf Larsson; Peter Nygren; Elin Lindhagen
Journal:  Med Oncol       Date:  2008-11-18       Impact factor: 3.064

7.  Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro.

Authors:  Elin Lindhagen; Linda Rickardson; Gary Elliott; Lorenzo Leoni; Peter Nygren; Rolf Larsson; Anna Aleskog
Journal:  Invest New Drugs       Date:  2007-04-18       Impact factor: 3.850

8.  Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system.

Authors:  Jenny Felth; Karolina Lesiak-Mieczkowska; Padraig D'Arcy; Caroline Haglund; Joachim Gullbo; Rolf Larsson; Stig Linder; Lars Bohlin; Mårten Fryknäs; Linda Rickardson
Journal:  Invest New Drugs       Date:  2012-11-20       Impact factor: 3.850

9.  Brunn: an open source laboratory information system for microplates with a graphical plate layout design process.

Authors:  Jonathan Alvarsson; Claes Andersson; Ola Spjuth; Rolf Larsson; Jarl E S Wikberg
Journal:  BMC Bioinformatics       Date:  2011-05-20       Impact factor: 3.307

10.  Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells.

Authors:  Lili Milani; Manu Gupta; Malin Andersen; Sumeer Dhar; Mårten Fryknäs; Anders Isaksson; Rolf Larsson; Ann-Christine Syvänen
Journal:  Nucleic Acids Res       Date:  2007-01-31       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.